Navigation Links
$300,000 CIHR grant awarded to Medicago, the Research Institute of the MUHC and McGill University
Date:3/1/2010

This release is available in French.

Montreal, March 1, 2010 The Canadian Institutes of Health Research (CIHR) have awarded a $300,000 grant for research focusing on the nature of the immune response induced by the action mechanisms of plant-made Virus-Like Particles (VLP) to Dr. Louis Vezina, Chief Scientific Officer of Medicago and to Dr. Brian Ward and Dr. Ciriaco Piccirillo of the Research Institute of the McGill University Health Centre (RI MUHC) and McGill University.

"Receiving this government grant further acknowledges the scientific merit of our joint research efforts with McGill in the development of leading plant-based VLP vaccines," said Andy Sheldon, President and Chief Executive Officer of Medicago. "A deeper understanding of all potential benefits of the immune response generated by our VLPs will allow us to further differentiate and better position our product on the market. We believe our VLP vaccines will be the preferred option to increase the speed of a public health response in the event of a pandemic outbreak as our VLP plant-based manufacturing process is very efficient with a relatively low capital cost."

"VLPs are among the most promising technologies to produce the next generation of vaccines. The technical simplicity and low cost of VLP production in plants add great value to this delivery system as it is the first platform technology with a realistic potential to address the needs of the developing world for low cost vaccines," said Brian Ward, Associate Director of the Research Institute at the MUHC (Fundamental Science). " I am delighted that we have secured this grant from CIHR as a sophisticated understanding of how these vaccines interact with the immune system is of considerable importance."

Medicago recently reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response. Full results of the Phase I trial will be submitted for publication in a scientific journal and will be available in the coming months.

Dr. Brian Ward, is Associate Director of the Research Institute at the MUHC (Fundamental Science), Co-Director of the MUHC Vaccine Evaluation Centre and also a Professor in the Faculty of Medicine at McGill University. Dr. Ciriaco Piccirillo is Canada Research Chair, Principal Investigator of the Laboratory of Immuno-regulation, Director of the FOCIS Center of Excellence, Director of the Immune Phenotyping Platform at the RI MUHC and Associate Professor of Microbiology and Immunology at McGill University


'/>"/>

Contact: Julie Robert
julie.robert@muhc.mcgill.ca
514-843-1560
McGill University Health Centre
Source:Eurekalert

Related medicine news :

1. Regence Foundation Awards More Than $300,000 in Grants to Promote Hospital-Based Palliative Care
2. 18th Annual Texas Autism Conference Returns To Corpus Christi, Makes Nearly $300,000 Economic Impact
3. CVS Caremark Charitable Trust Invests $300,000 in Easter Seals' Autism Services for Young Children
4. GNC Helps to Raise Over $300,000 for National MS Society in First 30 Days of Ride Across America by Phil Keoghan of CBS The Amazing Race
5. Talk About Curing Autism Receives $300,000 Grant From Pacific Life Foundation to Provide Services for Families Affected by Autism in Orange County
6. UMass Medical School receives $300,000 from JDRF and Iacocca Foundation
7. UMass Consortium awarded $300,000 from Juvenile Diabetes Research Foundation and Iacocca Foundation
8. SPOC, Inc. announces completion of $300,000 follow-on investment by Connecticut Innovations
9. CVS/pharmacy Donates More Than $300,000 in Supplies to Aid Fire Relief Efforts in California
10. New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery
11. $250,000 Grant Awarded for Groundbreaking Ligament and Tendon Repair Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2017)... ... 24, 2017 , ... “The Gospel Truth Of The Bible: The Other Sheep”: the ceremonial laws ... Bible: The Other Sheep” is the creation of published author, Maurice Caines. Maurice Caines ... He has been a member of the Seventh-day Adventist Church for many years. ...
(Date:9/22/2017)... ... September 22, 2017 , ... MEDIA OPPORTUNITY: , Save Our Hospital - Albert ... why they are rallying against Mayo Clinic. Specifically, media can talk to steering committee ... (CEO) decision to close the Albert Lea hospital. , The rally aims to protect ...
(Date:9/22/2017)... Island, New York (PRWEB) , ... September 22, ... ... manufactures, delivers and assembles Passive House buildings, and Richard Pedranti Architect ... Prefabricated Passive House from the strategic partner’s Solsken Line of Model Homes ...
(Date:9/22/2017)... ... ... Happy Living’s mission - to improve the health and wellbeing of the ... delicious worlds of theatre and wines. , After watching Scott Barry perform on ... play into a book. The Greener The Grass ( https://www.happyliving.com/books/the-greener-the-grass ) was published on ...
(Date:9/22/2017)... ... September 22, 2017 , ... First Choice ... celebrating the one year anniversary of its Houston-Fallbrook facility. , “We are ... Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has been a ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017  Medical professionals ... and skills while treating their patients. Medical ... experience without involving patients. Simulation provides a ... can carry out procedures, refine techniques and ... Integration of new technology, such as augmented ...
(Date:9/6/2017)... 2017 NeuroRx, a clinical stage biopharma company developing ... (ASIB), has been granted Fast Track status by the US ... (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company ... this sequential therapy targeting patients who are admitted to Emergency ... ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
Breaking Medicine Technology: